Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation

Inclusion Criteria -

• Male or female, of any race, between 18 and 65 years of age, inclusive.
• Females must not be pregnant or lactating.
• Males and females of childbearing potential must agree to use contraception
• Body mass index between 18.0 and 29.9 kg/m2, inclusive.
• In good health, as determined by no clinically significant findings from medical history, 12-lead ECG and vital signs measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [eg, suspicion of Gilbert's syndrome based on total and direct bilirubin] is not acceptable) at screening and check-in, and from the physical examination at check-in, as assessed by the investigator or designee.
• Able to comprehend and are willing to sign the ICF and abide by the study restrictions.

Exclusion Criteria -

An individual who meets any of the following criteria at screening, unless otherwise stated, will be excluded from participation in this study:

Medical Conditions

• Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator or designee.
• History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator or designee.
• History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair are allowed).
• Any of the following:
• QTcF >450 ms in males or >470 ms in females, based on the longest value from the triplicate ECG measurements
• QRS duration >120 ms, based on the longest value from the triplicate ECG measurements
• PR interval >210 ms, based on the longest value from the triplicate ECG measurements
• findings which would make QTc measurements difficult or QTc data uninterpretable
• history of additional risk factors for torsades de pointes (eg, heart failure, hypokalemia, or family history of long QT syndrome).
• Participants with an increased risk of thromboembolic events (eg, history of recurrent venous thrombosis or Factor V Leiden mutation).
• Magnesium 1.2 × ULN.
• Congenital nonhemolytic hyperbilirubinemia.
• Hemoglobin value, neutrophil count (absolute), lymphocyte count (absolute), and/or platelet count ULN; participants with values that are borderline > ULN may be included, as determined by the investigator or designee.
• eGFR 21 units per week for males and >14 units for females. One unit of alcohol equals 12 oz (360 mL) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL) wine.
• Positive urine drug screen at screening. Positive alcohol test result or positive urine drug screen at check-in.
• History of alcoholism or drug/chemical abuse within 2 years prior to check-in.

Other

• Use of tobacco- or nicotine-containing products within 3 months prior to check-in.
• Receipt of blood products within 2 months prior to check-in.
• Donation of blood from 3 months prior to screening, plasma from 2 weeks prior to screening, or platelets from 6 weeks prior to screening.
• Poor peripheral venous access.
• Participants who, in the opinion of the investigator or designee, should not participate in this study.